Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.78 |
| ▸ | CES1 | P23141 | 2/20 | 0.78 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811737 | 0.94 | CES2 (0.69) | CES2CES1SRD5A2PTPN1CPT1B | |
| SCHEMBL3172262 | 0.88 | CES2 (1.00) | CES2CES1SRD5A2PTPN1GSK3B | |
| SCHEMBL2834217 | 0.84 | CES2 (0.83) | CES2CES1SRD5A2PTPN1GSK3B | |
| SCHEMBL9042059 | 0.84 | CES2 (0.56) | CES2CES1PTPN1CYP1A1MAOB | |
| SCHEMBL78879 | 0.81 | SRD5A2 (0.87) | CES2CES1SRD5A2PTPN1GSK3B | |
| SCHEMBL1330891 | 0.81 | SRD5A2 (0.87) | CES2CES1SRD5A2PTPN1GSK3B | |
| SCHEMBL1435351 | 0.80 | CES2 (0.75) | CES2CES1SRD5A2PTPN1GSK3B | |
| Potassium Ion SCHEMBL22587990 | 0.80 | CES2 (0.75) | CES2CES1SRD5A2PTPN1GSK3B | |
| SCHEMBL5899483 | 0.80 | CES2 (0.75) | CES2CES1SRD5A2PTPN1GSK3B | |
| SCHEMBL20010796 | 0.80 | CES2 (0.83) | CES2CES1SRD5A2PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026917-A | Benzocyanine derivative for detecting peroxynitrosyl, and preparation method and application thereof | 海南医学院 | 2024-05-14 | — | — | CN | claimed |
| CN-111978201-B | Synthesis method of N, N' -diaryl benzoyl hydrazine compound | 甘肃农业大学 | 2023-01-03 | — | — | CN | claimed |
| CN-111978201-A | Synthesis method of N, N' -diaryl benzoyl hydrazine compound | 甘肃农业大学 | 2020-11-24 | — | — | CN | claimed |
| WO-2025056724-A1 | IMINOAMIDE-TYPE COMPOUNDS AS LIGANDS FOR COPPER-CATALYZED COUPLING REACTIONS OF (HETERO)ARYL HALIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-20 | — | — | WO | disclosed |
| CN-118026917-A | Benzocyanine derivative for detecting peroxynitrosyl, and preparation method and application thereof | 海南医学院 | 2024-05-14 | — | — | CN | disclosed |
| CN-111978201-B | Synthesis method of N, N' -diaryl benzoyl hydrazine compound | 甘肃农业大学 | 2023-01-03 | — | — | CN | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111423394-B | Synthesis method of 1,3, 4-oxadiazole heterocyclic compound | 常州大学 | 2021-11-23 | — | — | CN | disclosed |
| US-20200385328-A1 | METHOD FOR PRODUCING BENZOYL FORMIC ACID COMPOUND AND PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| CN-111978201-A | Synthesis method of N, N' -diaryl benzoyl hydrazine compound | 甘肃农业大学 | 2020-11-24 | — | — | CN | disclosed |
| CN-111423394-A | Synthesis method of 1,3, 4-oxadiazole heterocyclic compound | 常州大学 | 2020-07-17 | — | — | CN | disclosed |
| EP-2148869-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-0915856-A4 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6271249-B1 | Diphenyl imidazoles as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6077861-A | MODULATORS OF THE LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM (BK) CHANNELS, THEREFORE, USEFUL IN THE TREATMENT OF ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| CN-1226803-A | Diphenyl heterocycles as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 1999-08-25 | — | — | CN | disclosed |
| EP-0915856-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998004135-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385328-A1 | METHOD FOR PRODUCING BENZOYL FORMIC ACID COMPOUND AND PYRIDAZINE COMPOUND | SDHA, FDPS, NDUFS5 | CES2 3534/4885CES1 4147/4885SRD5A2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.